BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29022484)

  • 1. Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma.
    Cho O; Chun M; Oh YT; Noh OK; Chang SJ; Ryu HS; Lee EJ
    Tumour Biol; 2017 Oct; 39(10):1010428317733144. PubMed ID: 29022484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results and prognostic factors in patients with stage III-IVA squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy from a single institution study.
    Kudaka W; Nagai Y; Toita T; Inamine M; Asato K; Nakamoto T; Wakayama A; Ooyama T; Tokura A; Murayama S; Aoki Y
    Int J Clin Oncol; 2013 Oct; 18(5):916-21. PubMed ID: 22898910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution.
    Parker K; Gallop-Evans E; Hanna L; Adams M
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):140-6. PubMed ID: 18922646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy.
    Onal C; Yildirim BA; Guler OC; Mertsoylu H
    Int J Gynecol Cancer; 2018 Oct; 28(8):1553-1559. PubMed ID: 30247248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.
    Li X; Wei LC; Zhang Y; Zhao LN; Li WW; Ping LJ; Dang YZ; Hu J; Shi M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1472-9. PubMed ID: 27400321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
    Lim A; Sia S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone.
    Mabuchi S; Ugaki H; Isohashi F; Yoshioka Y; Temma K; Yada-Hashimoto N; Takeda T; Yamamoto T; Yoshino K; Nakajima R; Kuragaki C; Morishige K; Enomoto T; Inoue T; Kimura T
    Gynecol Obstet Invest; 2010; 69(4):224-232. PubMed ID: 20068328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer.
    Toita T; Moromizato H; Ogawa K; Kakinohana Y; Maehama T; Kanazawa K; Murayama S
    Gynecol Oncol; 2005 Mar; 96(3):665-70. PubMed ID: 15721409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematological parameters during concurrent chemoradiotherapy as potential prognosticators in patients with stage IIB cervical cancer.
    Cho O; Noh OK; Oh YT; Chang SJ; Ryu HS; Lee EJ; Chun M
    Tumour Biol; 2017 Feb; 39(2):1010428317694306. PubMed ID: 28222668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia.
    Kato S; Ohno T; Thephamongkhol K; Chansilpa Y; Yuxing Y; Devi CR; Bustam AZ; Calaguas MJ; de los Reyes RH; Cho CK; Dung TA; Supriana N; Mizuno H; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):751-7. PubMed ID: 19836154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma].
    Zeng SY; Li LY; Shu KY; Pan M; Li HP; Luo B
    Ai Zheng; 2008 Sep; 27(9):942-6. PubMed ID: 18799032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.
    Zhang MQ; Liu SP; Wang XE
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):821-7. PubMed ID: 20207507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
    Li XF; Li YH; Gao YN; Li CL; Yue HZ; Xu G; Li DM; Su X
    Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):763-7. PubMed ID: 24406134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application value of reduced field intensity modulated radiation therapy for advanced cervical cancer].
    DU XL; Sheng XG; Wang C; Yu H; Song QQ; Pan CX
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):925-31. PubMed ID: 24506963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of Escalating Relative High-dose-rate Intracavitary Brachytherapy Dose in Stage IIB Cervical Cancer.
    Cho O; Noh OK; Oh YT; Chang SJ; Chun M
    Anticancer Res; 2017 Jan; 37(1):327-334. PubMed ID: 28011510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer.
    Cho O; Chun M; Chang SJ; Oh YT; Noh OK
    Anticancer Res; 2016 Jul; 36(7):3541-7. PubMed ID: 27354621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcome of medium-dose-rate intracavitary brachytherapy for carcinoma of the uterine cervix: comparison with low-dose-rate intracavitary brachytherapy.
    Kaneyasu Y; Kita M; Okawa T; Maebayashi K; Kohno M; Sonoda T; Hirabayashi H; Nagata Y; Mitsuhashi N
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):137-45. PubMed ID: 22285665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.